Plot of gender ratio by six birth decades in MS patients stratified by Latitude.

<p> <i>p-value for trend *0.0425; **&lt;0.0001.</i></p

Sex ratio, percent of relapsing onset, mean age at onset and mean time from onset to diagnosis by birth decades in female (F) and male (M) MS patients.

*<p> <i>15996 pts; p-value for trend 0.032; ^Λ14543 pts; °11998 pts; § p&lt;0.05 sex M vs. F.</i></p><p>RR = Relapsing remitting; PP = Primary progressive.</p

Sex ratio, percent of relapsing onset, mean age at onset and mean time from onset to diagnosis by birth decades and latitude in female (F) and male (M) MS patients.

<p>RR = Relapsing remitting; PP = Primary progressive.</p

Plot of gender ratio by six birth decades in MS patients from Northern and Southern Europe.

<p> <i>p-value for trend *0.0426; **&lt;0.0004.</i></p

List of Countries with over one hundred cases, divided into three latitude areas.

<p>List of Countries with over one hundred cases, divided into three latitude areas.</p

Exposure to treatment with interferon β-1a SC thrice weekly.

<p>Numbers of patients treated with Rebif recorded within the MSBase registry (n = 4678) and stratified by time on treatment are shown. Red bar in year 1 indicates the proportion of patients in whom dose escalation was a planned procedure. TIW, three times weekly.</p

Discontinuation events.

<p>Data are presented as number of discontinuation events with annual probability of discontinuation stratified by recorded reasons for discontinuation. The events were recorded in all patients within the MSBase ever treated with Rebif. Escalations of treatment dosage planned as part of the treatment initiation protocol (i.e. occurring within the initial 6 months of treatment with Rebif 22 µg) were excluded.</p

Baseline demographic and clinical data in patients unmatched and matched by the propensity score.

<p>CIS, clinical isolated syndrome; EDSS, Expanded Disability Status Scale; MS, multiple sclerosis; PPMS, primary progressive multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; SD, standard deviation; SPMS, secondary progressive multiple sclerosis.</p

Likelihood of discontinuation by exposure to treatment.

<p>Overall proportion of treatment discontinuations in patients treated with either Rebif dosage is shown (left). Discontinuation rates by the recorded reasons are shown. Hazard ratio (HR) is given where significantly different from 1, dashed lines represent 95% confidence intervals. Planned dose escalations within the first year of treatment are not included. HR, hazard ratio; TIW, three times weekly.</p

Kaplan-Meier plots for the proportion of patients free from clinical relapses.

<p>No statistically significant differences between the treatment dosages were observed. MRI, magnetic resonance imaging; TIW, three times weekly.</p